Thematic meeting: Targeted Protein Degradation



This One-Day Thematic Meeting on « Targeted Protein Degradation: past, current and future strategies» organized by the Société de Chimie Thérapeutique (SCT) is at the frontier of developing new health technologies for the benefit of patients. This one-day symposium is a great opportunity for 8 European and US “Targeting Protein Degradation” experts from academy and industry to share recent results from their research.

  • Registration is open:  link

Deadline May 26th, 2024.

  • Date & Location

    • Thursday, 30th May 2024. 9 am - 5 pm
    • Sanofi Gentilly Campus, 80 rue Raspail, 94250 Gentilly, France

  • Programme
    • 9h00 - 09h30          Welcome & Coffee

    • 09h30 - 10h15        Prof. Daniel Nomura (Berkeley)

                                         Reimagining Druggability using Chemoproteomic Platforms

    • 10h15 - 10h45        Dr. Martin Schroeder (Novartis)

                                         Novel and reversible DCAF1 ligands expand the TPD-toolbox

    • 10H45 - 11h15        Coffee break

    • 11h15 - 12h00        Prof. Nicolas Thomä (Lausanne University)

                                         How to drug and degrade oncogenic transcription factors

    • 12h00 - 12h30        Dr. Ester Morreale (Crick Institute)

                                        Enabling targeted protein degradation in bacteria

    • 12h30 - 12h45        Promega presentation     The use of bioluminescence in the screening of DecoyTAC

    • 12h45 - 14h00        Lunch & Exposition

    • 14H00 -14h45        Prof. Ivan Dikic (Max Planck Institut of Bio)

                                        Discovery of novel molecular glues and anti-microbial PROTACs

    • 14h45 - 15h15       Dr. Manfred Koegl (Boehringer Ingelheim)

                                        Breaking Bad Proteins: Targeted Protein Degradation in Oncology

    • 15h15 -15h35        Coffee Break

    • 15h35 - 16h05       Dr. Samir Jegham  (Sanofi)

Opportunities And Challenges: Case study of the SAR444656 the 1st orally bioavailable clinical IRAK4 Degrader for the  treatment of autoimmune diseases.    

    • 16h05 - 16h35       Dr Kirsten McAulay (Dundee University, CETP)

                                        PROTAC Design for Oncology Targets – an Industry-Academia Collaboration

    • 16h35 - 17h05       Prof. Anne-Sophie Voisin-Chiret (Caen university)

Targeted protein degradation, a groundbreaking strategy for drug discovery. Application to the degradation of the Mcl-1 protein as a promising route for developing novel cancer therapeutics.

  • Organizing committee:
    • Y. Foricher (SANOFI & SCT)
    • G. Laconde (OXELTIS & SCT)
    • JY Ortholand (Edelris & SCT)
    • M Duca (CNRS & SCT)